7C02
Crystal structure of dimeric MERS-CoV receptor binding domain
Summary for 7C02
Entry DOI | 10.2210/pdb7c02/pdb |
Descriptor | Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose (2 entities in total) |
Functional Keywords | mers-cov, receptor binding domain, vaccine, virus, viral protein |
Biological source | Middle East respiratory syndrome-related coronavirus |
Total number of polymer chains | 2 |
Total formula weight | 54450.10 |
Authors | |
Primary citation | Dai, L.,Zheng, T.,Xu, K.,Han, Y.,Xu, L.,Huang, E.,An, Y.,Cheng, Y.,Li, S.,Liu, M.,Yang, M.,Li, Y.,Cheng, H.,Yuan, Y.,Zhang, W.,Ke, C.,Wong, G.,Qi, J.,Qin, C.,Yan, J.,Gao, G.F. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell, 182:722-, 2020 Cited by PubMed Abstract: Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats. PubMed: 32645327DOI: 10.1016/j.cell.2020.06.035 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.91 Å) |
Structure validation
Download full validation report
